BIOMEA FUSION INC
BMEANASDAQ🏆 #3282 by market capEarnings Nov 3US Equity
$1.30▲ $0.02 (+1.17%)
Market closed · at close1h—
24h▲ 1.2%
7d▲ 2.8%
14d▲ 5.7%
30d▼ 3.4%
1y▼ 21.3%
🏦Market Cap
$94M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
61
Fair
Trading Snapshot
- Day Range
- $1.29 – $1.31
- 52-Week Range
- $0.87 – $2.99
- Volume
- $3.81B
- Avg Volume
- $2.84B
- Shares Outstanding
- 72.3M
- Next Earnings
- Oct 3, 2026
Fundamentals Snapshot
- Annual Revenue
- $11M
- Last Q Revenue
- $3M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-0.50
- Dividend Yield
- —
Why Investors Own BMEA
- ✓High-growth profile — revenue up +22.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 74% gross margin and 25% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$11M▲ +17.0% YoY
Gross Margin (TTM)
74.4%▲ +2.7% YoY
Operating Income (TTM)
$3M▲ +17.0% YoY
Free Cash Flow (TTM)
$3M▲ +17.0% YoY
About BIOMEA FUSION INC
Biomea Fusion, Inc. is a biopharmaceutical firm dedicated to discovering and developing innovative covalent small molecule therapies. These treatments are specifically designed for individuals suffering from genetically defined cancers and various metabolic ailments. The company's primary drug candidate, BMF-219, is a potent and selective covalent inhibitor of menin, engineered for oral administration. Menin plays a crucial role as a transcriptional regulator in the abnormal signaling pathways found across numerous cancer types. Established in 2017, Biomea Fusion's operations are headquartered in Redwood City, California.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Fair
61/100
Analyst Ratings
ⓘConsensus
Buy
13 analysts
Strong Buy5
Buy6
Hold1
Sell1
Strong Sell0
Ratings as of Aug 2026